Kiniksa Pharmaceuticals Reports Q3 2026 Financial Results

What Happened
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 8‑K on July 28, 2026 to disclose that it issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is furnished with the 8‑K as Exhibit 99.1; the filing itself notes the release date but does not reproduce detailed financial tables in-line.

Key Details

• Filing date: July 28, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: quarter ended June 30, 2026.
• Exhibit provided: Exhibit 99.1 = press release announcing the quarter’s results (Exhibit 104 interactive XBRL cover page also included).
• Report signed by Douglas Barry, Senior VP, Chief Legal Officer and Secretary.

Why It Matters
Quarterly results (earnings, revenue, cash position and any guidance) are material to investors because they show recent business performance and can affect the stock price and near‑term company outlook. This Form 8‑K indicates Kiniksa has released those results — investors should read the Exhibit 99.1 press release for the actual revenue, net income/loss, operating metrics and any management commentary, and follow up with the company’s earnings call or subsequent SEC filings (e.g., 10‑Q) for full financial details.